title: The use of iodinated contrast media in patients with end-stage renal disease.
abstract: Iodinated contrast agents are well tolerated in ESRD patients. Certain types of ICM, i.e., LOCM and the nonionic agents are associated with better safety profiles. Current available evidence, although not optimal, does not support the need for additional hemodialysis for ICM removal to preserve residual renal function or to treat other potential toxicities of ICM. However, limiting exposure to ICM is a prudent measure in ESRD patients given ICM’s potential toxicity; close monitoring of patients with poor cardiac function is also recommended in subjects receiving higher doses of ICM, especially those receiving HOCM.
authors.affiliation: Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia.
authors.forename: Sana F
authors.initials: SF
authors.lastname: Khan
authors.forename: Kambiz
authors.initials: K
authors.lastname: Kalantari
mesh_terms: D003287:Contrast Media / Q000493:pharmacokinetics*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D006435:Renal Dialysis; D014283:Triiodobenzoic Acids / Q000493:pharmacokinetics*
chemical_list: D003287:Contrast Media; D014283:Triiodobenzoic Acids